Related Experiment Videos
Prognostic value of serum creatine kinase brain isoenzyme in term babies with perinatal hypoxic injuries
Insights
High concentrations of creatine kinase brain isoenzyme (CK-BB) in newborns may indicate poor neurological outcomes. Early CK-BB measurement can help identify infants at risk for developmental issues following perinatal hypoxic damage.
Area of Science:
- Biochemistry
- Neurology
- Neonatology
Background:
- Brain injury can lead to the release of creatine kinase brain isoenzyme (CK-BB) into the serum.
- Perinatal hypoxic damage poses a risk to term infants' neurological development.
Purpose of the Study:
- To investigate the correlation between serum CK-BB concentration and neurodevelopmental outcome in term infants at risk for perinatal hypoxic damage.
- To assess the clinical utility of early CK-BB measurement in identifying high-risk newborns.
Main Methods:
- Serial measurement of serum CK-BB concentration in 80 term infants using a new, highly sensitive enzyme analysis method.
- Neurodevelopmental outcome assessment at 12 months of age.
Main Results:
- Infants with high serum CK-BB concentrations showed a statistically significant higher frequency of poor short-term outcomes (p < 0.02).
- A correlation was observed between elevated CK-BB levels and adverse neurodevelopmental sequelae.
Conclusions:
- Early measurement of serum CK-BB may serve as a valuable clinical tool.
- Identifying newborns at high risk for neurological or developmental sequelae can be facilitated by CK-BB assessment.
Abstract:
Creatine kinase brain isoenzyme (CK-BB) may be released into the serum after brain injury. Its concentration was measured serially in a group of 80 term infants at risk of perinatal hypoxic damage. Their neurodevelopmental outcome was furthermore assessed at 12 months of age. Our results are consistent with the hypothesis that infants with high CK-BB concentration, measured in serum with a new and very sensitive method for enzyme analysis, have more frequently poor short-term outcome (p less than 0.02). These data suggest that early CK-BB measurement may be clinically useful to identify newborns at high risk for neurologic or developmental sequelae.